Anti-SAE antibodies in autoimmune myositis: Identification by unlabelled protein immunoprecipitation in an Italian patient cohort

Tarricone, Elena; Ghirardello, Anna; Rampudda, Mariaelisa; Bassi, Nicola; Punzi, Leonardo; Doria, Andrea

doi:10.1016/j.jim.2012.07.019

Cited by 101 publications

(61 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One female patient had DM-RA overlapping syndromes. The comparison of our results for the frequency of this antibody with the results of other studies [61][62][63][64] can be seen in Table 5.…”

Section: Positive Anti-sae Patientssupporting

confidence: 62%

Four dermatomyositis-specific autoantibodies—anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5—in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort

Bodoki

Nagy‐Vincze

Griger

et al. 2014

Autoimmunity Reviews

101

View full text Add to dashboard Cite

Section: Positive Anti-sae Patientssupporting

confidence: 62%

Four dermatomyositis-specific autoantibodies—anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5—in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort

Bodoki

Nagy‐Vincze

Griger

et al. 2014

Autoimmunity Reviews

101

View full text Add to dashboard Cite

“…AutoAb against small ubiquitin-like modifier activating enzyme (SAE) has now been described in a number of adult DM cohorts with varying frequency of 1.5-8 % [75][76][77][78][79]. Patients tend to present with hallmark skin disease first (amyopathic DM) and then progress to muscle weakness with systemic features including in some marked gastro-intestinal involvement with dysphagia [75,78].…”

Section: Anti-saementioning

confidence: 99%

The Clinical Features of Myositis-Associated Autoantibodies: a Review

Gunawardena

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases traditionally defined by clinical manifestations including skeletal muscle weakness, skin rashes, elevated skeletal muscle enzymes, and neurophysiological and/or histological evidence of muscle inflammation. Patients with myositis overlap can develop other features including parenchymal lung disease, inflammatory arthritis, gastrointestinal manifestations and marked constitutional symptoms. Although patients may be diagnosed as having polymyositis (PM) or dermatomyositis (DM) under the IIM spectrum, it is quite clear that disease course between subgroups of patients is different. For example, interstitial lung disease may predominate in some, whereas cutaneous complications, cancer risk, or severe refractory myopathy may be a significant feature in others. Therefore, tools that facilitate diagnosis and indicate which patients require more detailed investigation for disease complications are invaluable in clinical practice. The expanding field of autoantibodies (autoAbs) associated with connective tissue disease (CTD)-myositis overlap has generated considerable interest over the last few years. Using an immunological diagnostic approach, this group of heterogeneous conditions can be separated into a number of distinct clinical phenotypes. Rather than diagnose a patient as simply having PM, DM or overlap CTD, we can define syndromes to differentiate disease subsets that emphasise clinical outcomes and guide management. There are now over 15 CTD-myositis overlap autoAbs found in patients with a range of clinical manifestations including interstitial pneumonia, cutaneous disease, cancer-associated myositis and autoimmune-mediated necrotising myopathy. This review describes their diagnostic utility, potential role in disease monitoring and response to treatment. In the future, routine use of these autoAb will allow a stratified approach to managing this complex set of conditions.

show abstract

“…The representative MSAs/MAAs are listed in Table 1. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] In this article, we review the clinical significance and the new detection systems for MSAs/MAAs specifically associated with both myositis and interstitial lung disease (ILD).…”

Section: Introductionmentioning

confidence: 99%

Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease

Nakashima

Hosono

Mimori

2016

Lupus

104

View full text Add to dashboard Cite

Anti-aminoacyl-tRNA synthetase (ARS) and anti-melanoma differentiation-associated gene 5 ( MDA5) antibodies are closely associated with interstitial lung disease in polymyositis and dermatomyositis. Anti-ARS-positive patients develop common clinical characteristics termed anti-synthetase syndrome and share a common clinical course, in which they respond well to initial treatment with glucocorticoids but in which disease tends to recur when glucocorticoids are tapered. Anti- MDA5 antibody is associated with rapidly progressive interstitial lung disease and poor prognosis, particularly in Asia. Therefore, intensive immunosuppressive therapy is required for anti- MDA5-positive patients from the early phase of the disease. New enzyme-linked immunosorbent assays to detect anti-ARS and anti- MDA5 antibodies have recently been established and are suggested to be efficient and useful. These assays are expected to be widely applied in daily practice.

show abstract

Anti-SAE antibodies in autoimmune myositis: Identification by unlabelled protein immunoprecipitation in an Italian patient cohort

Cited by 101 publications

References 45 publications

Four dermatomyositis-specific autoantibodies—anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5—in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort

Four dermatomyositis-specific autoantibodies—anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5—in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort

The Clinical Features of Myositis-Associated Autoantibodies: a Review

Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease

Contact Info

Product

Resources

About